ESR1 and pituitary gland adenoma: Since both the estrogen/ERα and PRL/PRLR signaling pathways are recognized as pathogenic mediators of pituitary adenoma, these aforementioned findings suggest that estrogen/ERα and PRL/PRLR signaling may be involved in the therapeutic resistance of prolactinomas.